• Deutsch
Login

Open Access

  • Home
  • Search
  • Browse
  • Publish
  • FAQ
Schließen

Refine

Author

  • Heidenreich, Axel (2)
  • Albers, Peter (1)
  • Antony, Pia (1)
  • Bertz, Simone (1)
  • Classen, Johannes (1)
  • Dahl, Edgar (1)
  • Denzinger, Stefan (1)
  • Fiedler, David (1)
  • Gaisa, Nadine T. (1)
  • Geschwend, Jürgen (1)
+ more

Year of publication

  • 2014 (1)
  • 2010 (1)

Document Type

  • Article (2)

Language

  • English (2)

Has Fulltext

  • yes (2)

Keywords

  • - (2)
  • Bladder cancer (1)
  • Computed tomography (1)
  • Germ cell tumors (1)
  • Magnetic resonance imaging (1)
  • PET-CT (1)

Institute

  • Medizinische Fakultät (1)
  • Medizinische Fakultät -ohne weitere Spezifikation- (1)

2 search hits

  • 1 to 2
  • 10
  • 20
  • 50
  • 100

Sort by

  • Year
  • Year
  • Title
  • Title
  • Author
  • Author
Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society (2010)
Heidenreich, Axel ; Albers, Peter ; Classen, Johannes ; Graefen, Markus ; Geschwend, Jürgen ; Kotzerke, Jörg ; Krege, Susanne ; Lehmann, Jens ; Rohde, Detlef ; Schmidberger, Heinz ; Uder, Michael ; Zeeb, Hajo
Introduction: Imaging studies are an integral and important diagnostic modality to stage, to monitor and follow-up patients with metastatic urogenital cancer. The currently available guidelines on diagnosis and treatment of urogenital cancer do not provide the clinician with evidence-based recommendations for daily practice. Objectives: To develop scientifically valid recommendations with regard to the most appropriate imaging technique and the most useful time interval in metastatic urogenital cancer patients undergoing systemic therapy. Methods: A systematic literature review was performed searching MedLine, Embase and Web of Science databases using the terms prostate, renal cell, bladder and testis cancer in combination with the variables lymph node, lung, liver, bone metastases, chemotherapy and molecular therapy, and the search terms computed tomography, magnetic resonance imaging and positron emission tomography were applied. A total of 11,834 records were retrieved from all databases. The panel reviewed the records to identify articles with the highest level of evidence using the recommendation of the US Agency for Health Care Policy and Research. Conclusions: Contrast-enhanced computed tomography remains the standard imaging technique for monitoring of pulmonary, hepatic and lymph node metastases. Bone scintigraphy is still the most widely used imaging technique for the detection and follow-up of osseous lesions. For clinical trials it might be replaced by either PET-CT or MRI of the skeletal axis. Response assessment for patients treated with cytotoxic regime is best performed by the RECIST/WHO criteria; treatment response to molecular triggered therapy is best assessed by CT evaluating decrease in tumor size and density. Cross-sectional imaging studies for response assessment might be obtained after each 2 cycles of systemic therapy to early stratify responders from nonresponders.
Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours (2014)
Rose, Michael ; Gaisa, Nadine T. ; Antony, Pia ; Fiedler, David ; Heidenreich, Axel ; Otto, Wolfgang ; Denzinger, Stefan ; Bertz, Simone ; Hartmann, Arndt ; Karl, Alexander ; Knüchel, Ruth ; Dahl, Edgar
Inter-α-trypsin inhibitor heavy chain 5 (ITIH5) has been associated with tumour suppression in various cancers. However, its putative role in bladder cancer is completely unknown. Therefore, we initiated a study analysing ITIH5 expression as well as its prognostic and functional impact on human urothelial cancers (UCs). Expression analysis showed a clear down-regulation of ITIH5 mRNA in 61% (n = 45) of UCs, especially in muscle-invasive tumours (P < 0.001). ITIH5 loss in UCs was further evident on protein level (65.5%, n = 55) as detected by immunohistochemistry. DNA methylation analysis demonstrated tumour-specific ITIH5 promoter methylation in 50% of papillary none-invasive pTa (n = 30) and 68% of invasive (n = 28) UCs. Aberrant ITIH5 promoter methylation in bladder tumours was tightly linked (P < 0.001) with loss of ITIH5 mRNA expression, which was furthermore functionally confirmed by demethylation analysis in cell lines. Pyrosequencing analysis revealed that ITIH5 promoter hypermethylation was closely associated with progressive bladder cancers. Subsequently, a large cohort (n = 120) of clinically challenging pT1 high-grade UC was analysed for ITIH5 expression. Of clinical significance, we found an association between loss of ITIH5 expression and unfavourable prognosis of UC patients without distant metastasis at first diagnosis (recurrence-free survival; hazard ratio: 4.35, P = 0.048). Functionally, ITIH5 re-expression in human RT112 bladder cancer cells led to both suppression of cell migration and inhibition of colony spreading. Hence, we provide evidence that down-regulation of ITIH5 by aberrant DNA hypermethylation may provoke invasive phenotypes in human bladder cancer. Moreover, ITIH5 protein might become a prognostic biomarker for relapse risk stratification in high-grade UC patients.
  • 1 to 2

DINI-Zertifikat 2013     DINI-Zertifikat 2016     Members of COAR OPUS4 Logo

  • Contact
  • Imprint
  • Sitelinks